Yesterday, Sept. 1, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $375.00 to $2,371,915.78.

Highlighted Stocks Traded by Insiders:

Harvard Bioscience (HBIO) - FREE Research Report

Kennedy John F, who is Director at Harvard Bioscience, bought 2,000 shares at $4.33 on Sept. 1, 2015. Following this transaction, the Director owned 177,330 shares meaning that the stake was boosted by 1.14% with the 2,000-share transaction.

The shares most recently traded at $4.32, down $0.01, or 0.23% since the insider transaction. Historical insider transactions for Harvard Bioscience go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 118,500
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 17,103
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 382,271

The average volume for Harvard Bioscience has been 184,700 shares per day over the past 30 days. Harvard Bioscience has a market cap of $148.3 million and is part of the health care sector and health services industry. Shares are down 23.99% year-to-date as of the close of trading on Tuesday.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. Currently, there is 1 analyst who rates Harvard Bioscience a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HBIO - FREE

TheStreet Quant Ratings

rates Harvard Bioscience as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Harvard Bioscience Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NuStar GP Holdings (NSH) - FREE Research Report

Greehey William E, who is Director at NuStar GP Holdings, bought 70,097 shares at $33.57 on Sept. 1, 2015. Following this transaction, the Director owned 8.5 million shares meaning that the stake was boosted by 0.83% with the 70,097-share transaction.

The shares most recently traded at $33.07, down $0.50, or 1.52% since the insider transaction. Historical insider transactions for NuStar GP Holdings go as follows:

  • 4-Week # shares bought: 184,603
  • 12-Week # shares bought: 244,003
  • 24-Week # shares bought: 274,003

The average volume for NuStar GP Holdings has been 150,400 shares per day over the past 30 days. NuStar GP Holdings has a market cap of $1.4 billion and is part of the basic materials sector and energy industry. Shares are down 4.62% year-to-date as of the close of trading on Tuesday.

NuStar GP Holdings, LLC, through its ownership interests in NuStar Energy L.P., engages in the transportation of petroleum products and anhydrous ammonia; terminalling and storage of petroleum products; and marketing of petroleum products. The stock currently has a dividend yield of 6.57%. The company has a P/E ratio of 19.1. Currently, there are 3 analysts who rate NuStar GP Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NSH - FREE

TheStreet Quant Ratings

rates NuStar GP Holdings as a

hold

. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

NuStar GP Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioAmber (BIOA) - FREE Research Report

Ashworth Andrew P., who is Chief Financial Officer at BioAmber, bought 700 shares at $6.01 on Sept. 1, 2015. Following this transaction, the Chief Financial Officer owned 4,207 shares meaning that the stake was boosted by 19.96% with the 700-share transaction.

The shares most recently traded at $5.91, down $0.10, or 1.69% since the insider transaction. Historical insider transactions for BioAmber go as follows:

  • 4-Week # shares bought: 55,500
  • 12-Week # shares bought: 55,500
  • 24-Week # shares bought: 89,800

The average volume for BioAmber has been 55,300 shares per day over the past 30 days. BioAmber has a market cap of $152.8 million and is part of the basic materials sector and chemicals industry. Shares are down 31.23% year-to-date as of the close of trading on Tuesday.

BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various chemical market customers in the United States. The company has a P/E ratio of 4.0. Currently, there are 2 analysts who rate BioAmber a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIOA - FREE

TheStreet Quant Ratings

rates BioAmber as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and unimpressive growth in net income. Get the full

BioAmber Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.